Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan in Advanced Colorectal Cancer
NCT06464692Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of telisotuzumab adizutecan in colorectal cancer (CRC) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Dose-Limiting Toxicity up to 24 Months, Maximum observed plasma or serum concentration up to 24 Months and 4 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06464692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06464692.